Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Fruquintinib
Conditions
Interventions
Fruquintinib
Locations
2
United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Start Date
March 11, 2022
Primary Completion Date
October 25, 2022
Completion Date
October 25, 2022
Last Updated
October 31, 2022
NCT07324616
NCT07023354
NCT04271488
NCT05484206
NCT06952634
NCT06908954
Lead Sponsor
Hutchmed
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions